Key clinical point: FT596 – a universal, anti-CD19 chimeric antigen receptor natural killer cell therapy derived from a master induced pluripotent stem cell line – has demonstrated activity against B-cell malignancies.
Major finding: FT596 reduced tumor growth in mouse models of leukemia and lymphoma. When combined with rituximab, FT596 was able to overcome CD19 antigen escape.
Study details: Preclinical research.
Disclosures: The research was conducted by employees of Fate Therapeutics, the company developing FT596.
Goodridge JP et al. ASH 2019. Abstract 301.